These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38726264)

  • 41. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer.
    Al-Ejeh F; Simpson PT; Sanus JM; Klein K; Kalimutho M; Shi W; Miranda M; Kutasovic J; Raghavendra A; Madore J; Reid L; Krause L; Chenevix-Trench G; Lakhani SR; Khanna KK
    Oncogenesis; 2014 Apr; 3(4):e100. PubMed ID: 24752235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
    Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
    Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
    Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
    Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
    Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next-generation sequencing reveals altered gene expression and enriched pathways in triple-negative breast cancer cells treated with oleuropein and oleocanthal.
    Karousi P; Kontos CK; Papakotsi P; Kostakis IK; Skaltsounis AL; Scorilas A
    Funct Integr Genomics; 2023 Sep; 23(4):299. PubMed ID: 37707691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
    Liu Z; Ding M; Qiu P; Pan K; Guo Q
    Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression.
    Kuo WH; Chu PY; Wang CC; Huang PS; Chan SH
    Biol Direct; 2023 Aug; 18(1):44. PubMed ID: 37550720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
    Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
    Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.
    Liao M; Qin R; Huang W; Zhu HP; Peng F; Han B; Liu B
    J Hematol Oncol; 2022 Apr; 15(1):44. PubMed ID: 35414025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FGFR3 signaling and function in triple negative breast cancer.
    Chew NJ; Nguyen EV; Su SP; Novy K; Chan HC; Nguyen LK; Luu J; Simpson KJ; Lee RS; Daly RJ
    Cell Commun Signal; 2020 Jan; 18(1):13. PubMed ID: 31987043
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance.
    Boichuk S; Galembikova A; Sitenkov A; Khusnutdinov R; Dunaev P; Valeeva E; Usolova N
    Oncol Lett; 2017 Oct; 14(4):5039-5045. PubMed ID: 29085518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of Potential Key Genes Associated With the Pathogenesis, Metastasis, and Prognosis of Triple-Negative Breast Cancer on the Basis of Integrated Bioinformatics Analysis.
    Zhao B; Xu Y; Zhao Y; Shen S; Sun Q
    Front Oncol; 2020; 10():856. PubMed ID: 32596149
    [No Abstract]   [Full Text] [Related]  

  • 59. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ethyl acetate extract of Antenoron Filiforme inhibits the proliferation of triple negative breast cancer cells via suppressing Skp2/p21 signaling axis.
    Liao Y; Li S; An J; Yu X; Tan X; Gui Y; Wang Y; Huang L; Zhou S; Wang D
    Phytomedicine; 2023 Jul; 116():154856. PubMed ID: 37187035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.